Literature DB >> 1377362

Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation.

N A Clipstone1, G R Crabtree.   

Abstract

The immunosuppressive drugs cyclosporin A (CsA) and FK506 both interfere with a Ca(2+)-sensitive T-cell signal transduction pathway, thereby preventing the activation of specific transcription factors (such as NF-AT and NF-IL2A) involved in lymphokine gene expression. CsA and FK506 seem to act by interaction with their cognate intracellular receptors, cyclophilin and FKBP, respectively (see ref. 11 for review). The Ca2+/calmodulin-regulated phosphatase calcineurin is a major target of drug-isomerase complexes in vitro. We have therefore tested the hypothesis that this interaction is responsible for the in vivo effects of CsA/FK506. We report here that overexpression of calcineurin in Jurkat cells renders them more resistant to the effects of CsA and FK506 and augments both NFAT- and NFIL2A-dependent transcription. These results identify calcineurin as a key enzyme in the T-cell signal transduction cascade and provide biological evidence to support the notion that the interaction of drug-isomerase complexes with calcineurin underlies the molecular basis of CsA/FK506-mediated immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1377362     DOI: 10.1038/357695a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  437 in total

1.  Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway.

Authors:  C Nataraj; M I Oliverio; R B Mannon; P J Mannon; L P Audoly; C S Amuchastegui; P Ruiz; O Smithies; T M Coffman
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  Therapeutic drug monitoring of immunosuppressant drugs.

Authors:  A Johnston; D W Holt
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

3.  Cyclosporin: nephro-protective as well as nephrotoxic?

Authors:  P W Mathieson
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

4.  Vasorelaxation and inhibition of the voltage-operated Ca2+ channels by FK506 in the porcine coronary artery.

Authors:  T Yasutsune; N Kawakami; K Hirano; J Nishimura; H Yasui; K Kitamura; H Kanaide
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

5.  Spontaneous intracranial hypotension-hypovolemia associated with tacrolimus.

Authors:  Andrew H Ahn; Brian D Berman; William P Dillon
Journal:  Headache       Date:  2010-05-31       Impact factor: 5.887

6.  15-Deoxy-delta12,14-prostaglandin J2-glycerol ester, a putative metabolite of 2-arachidonyl glycerol, activates peroxisome proliferator activated receptor gamma.

Authors:  Priyadarshini Raman; Barbara L F Kaplan; Jerry T Thompson; John P Vanden Heuvel; Norbert E Kaminski
Journal:  Mol Pharmacol       Date:  2011-04-21       Impact factor: 4.436

7.  Involvement of hydrogen peroxide in asbestos-induced NFAT activation.

Authors:  Jingxia Li; Bihui Huang; Xianglin Shi; Vincent Castranova; Val Vallyathan; Chuanshu Huang
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

8.  Regulation of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus at concentrations that inhibit calcineurin activity and involving the transcription factor CREB.

Authors:  Elke Oetjen; Daniela Grapentin; Roland Blume; Michael Seeger; Doris Krause; Anke Eggers; Willhart Knepel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-20       Impact factor: 3.000

9.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex.

Authors:  Hui-Hua Li; Vishram Kedar; Chunlian Zhang; Holly McDonough; Ranjana Arya; Da-Zhi Wang; Cam Patterson
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

10.  A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type.

Authors:  E R Chin; E N Olson; J A Richardson; Q Yang; C Humphries; J M Shelton; H Wu; W Zhu; R Bassel-Duby; R S Williams
Journal:  Genes Dev       Date:  1998-08-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.